To test whether the STOPGAP II approach can improve treatment options for patients with stage 4 gastric cancer and peritoneal carcinomatosis.
Approach:
Background: STOPGAP II is a national randomized clinical trial that builds on the findings of STOPGAP I, which was initiated due to the increasing number of younger patients diagnosed with advanced gastric cancer.
Trial Design: The trial is designed to evaluate the safety and feasibility of new treatment options for gastric carcinomatosis.
Key Findings:
STOPGAP I established safety and feasibility for advancing to a national trial.
STOPGAP II is currently open and accruing participants ahead of expectations.
Interpretation:
Conclusion:
STOPGAP II addresses treatment options for advanced gastric cancer.
